Targeting B7-H3 to reduce tumor growth in a type of childhood brain cancer

Silencing B7-H3 mitigates tumor aggressiveness in group 3 medulloblastoma

NIH-funded research University of Nebraska Medical Center · NIH-11042380

This study is looking at a type of brain cancer in kids called medulloblastoma, especially the group 3 kind that is tough to treat, and it’s testing a new way to block a protein that helps the cancer grow, hoping to find better treatments to help kids with this condition.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionUniversity of Nebraska Medical Center NIH-funded
Lab location1 site (Omaha, United States)
Project IDNIH-11042380 on NIH RePORTER

What this research studies

This research focuses on medulloblastoma, a common and aggressive brain cancer in children, particularly the group 3 subtype which has a low survival rate. The study aims to silence a protein called B7-H3 that is linked to cancer cell growth and metastasis. By using a specific compound, B7-H3-Ni1, researchers hope to inhibit the growth and invasiveness of these cancer cells. The approach involves screening various molecules to find effective treatments that can potentially improve outcomes for affected children.

Who could benefit from this research

Good fit: Ideal candidates for this research are children under 11 years old diagnosed with group 3 medulloblastoma.

Not a fit: Patients with other types of medulloblastoma or those over 11 years old may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new targeted therapies that significantly improve survival rates for children with aggressive medulloblastoma.

How similar studies have performed: Previous research has shown promise in targeting similar pathways in other aggressive cancers, suggesting potential for success in this novel approach.

Where this research is happening

Omaha, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agentsanti-cancer drug
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.